Join LifeNet Health LifeSciences for our first Assay Services webinar, focusing on Dermal Absorption. This session explores in vitro permeation testing, a crucial method for assessing a compound’s potential to penetrate the skin and reach systemic circulation.
LifeNet Health leverages 40+ years as a global leader in tissue banking and organ procurement to support this assay by processing highly controlled and consistent excised human skin with preserved anatomical structure and barrier properties. Following OECD Test Guideline 428 and SCCS/1358/10, recognized as gold standards for dermal absorption studies, we ensure regulatory compliance and high-quality data. Our GLP-compliant services offer reliable, reproducible results that align with global guidelines, providing essential support for product safety testing and regulatory submissions.
Attendees will learn how our assays help predict dermal absorption of compounds and support safer, more effective product development.
Key Topics Include:
- Human-Relevant Data: Learn why in vitro dermal absorption assays using human skin are the gold standard for accurate skin permeation data.
- Regulatory Compliance: Discover how LifeNet Health LifeSciences ensures regulatory acceptance by aligning with OECD Test Guideline 428, SCCS/1358/10, and other internationally recognized standards.
- Customizable Testing: Understand the flexibility of our assays, including tailored analyte detection and skin donor characteristics.
- Streamlined R&D Support: See how our assays aid in early product development, improving safety profiles and speeding up regulatory submissions.
- Comprehensive Dermal Testing: Explore our full portfolio of dermal assays, including irritation, corrosion, and sensitization, for a complete skin safety evaluation.
- Ethical & Sustainable Skin Sourcing: Benefit from LifeNet Health’s vertically integrated skin procurement model, from organ procurement to research use, designed to ensure ethically sourced, high quality human tissue that supports reproducible in vitro testing and reduces reliance on animal models.
- Categories: Clinical Research, Drug Discovery & Development, Pharmacology, Toxicology
- Tags: clinical research, drug development, drug discovery, drug safety, drug testing, in vitro, regulatory compliance, safety pharmacology
Presenters
Alec Salminen, PhD
Manager
In Vitro Assay Services
LifeNet Health LifeSciences
Alec Salminen, PhD is Manager of the In Vitro Assay Services group at LifeNet Health LifeSciences, leading a team that provides comprehensive in vitro toxicology testing to industry, government, and academic partners.
Brent Gilbert
Assay Services Sales Director
LifeNet Health LifeSciences
Brent Gilbert is a Scientific Sales Director at LifeNet Health with 20 years of experience working in contract research, and is currently responsible for interaction with and development of personal care, cosmetic, chemical and medical device clients worldwide.
Production Partner
LifeNet Health LifeSciences
LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeNet Health LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services.
Additional Content From LifeNet Health LifeSciences
Improving Confidence in Thyroid Hormone Disruption Assessment Using a Novel Human-Relevant In Vitro Model
Learn how an emerging NAM is helping advance more efficient, human-relevant strategies for assessing thyroid hormone disruption while reducing reliance on animal testing.
Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model
In this exclusive session, Stephanie Piekos, PhD, Senior Scientist at Boehringer Ingelheim, shares insights into the challenges of evaluating AO substrates and how more predictive, human-relevant models are shaping the future of DMPK studies.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join us to learn how in-depth in vivo phenotyping using patient-relevant models can improve preclinical decision-making.
